Objective: Reported are initial 12-month outcomes of patients with chronic symptomatic aortic dissection managed by the Streamliner Multilayer Flow Modulator (SMFM; Cardiatis, Isnes, Belgium). Primary end points were freedom from rupture-and aortic-related death, and reduction in false lumen index. Secondary end points were patency of great vessels and visceral branches, and freedom of stroke, paraplegia, and renal failure.
The management of type B aortic dissection (TBAD) has evolved, and thoracic endovascular aneurysm repair (TEVAR) is safe and life-saving. [1] [2] [3] [4] [5] The ability to remodel the dissected aorta as a result of scaffolding, means that pre-emptive endovascular treatment is being considered and supported by results of the Investigation of Stent Grafts in Aortic Dissection with extended follow-up (INSTEAD-XL) trial 6 and the Acute Dissection: Stent graft OR Best medical therapy (ADSORB) 7 trial. An aggressive approach to intervention is driven by evidence that the majority of patients with TBAD will fail medical therapy over time, and patients who undergo aortic intervention have a survival advantage over those treated with medical management alone. 8 Advancing chronicity of TBAD increases the complexity of the pathologic anatomy, with septal rigidity and false lumen aneurysmal expansion. Multiple adjunctive procedures at the initial treatment and during follow-up are usually necessary, and no clear end point in therapy has yet been defined for patients with residual false lumen flow.
This report from the Streamliner Multilayer Flow Modulator (SMFM; Cardiatis, Isnes, Belgium) global registry, examines the off-label use of the SMFM in the treatment of chronic symptomatic aortic dissection (CSAD) in patients whom alternative treatment options such as fenestration and branched aortic endografting or open surgical repair were not feasible or available. 9, 10 The SMFM is a multilayered cobalt alloy bare metal implantable device. The three-dimensional nature of the SMFM comprises multiple interlocked layers of wire, braided together to create a mesh. This mesh design alters blood flow from turbulent to laminar, inducing positive shear stresses along the aortic wall to promote endothelialization along the luminal aspect of the SMFM and thrombosis of the aneurysm. This device differs from traditional endovascular stent grafts given that it does not completely exclude blood flow from the aneurysm because of its porosity; rather its design alters the rate and direction of blood flow. As long as the branches are fully patent before SMFM implantation, the SMFM permits enhanced blood flow through the mesh wall into native branch arteries, negating the requirement for branching or fenestration to maintain visceral and spinal perfusion. 10 
METHODS
This study is a retrospective analysis of a prospectively maintained global registry focusing specifically on patients with CSAD, treated with the SMFM device between 2010 and 2015. The SMFM device currently does not hold a European Conformity mark or approval from the U. S. Food and Drug Administration for treatment of aortic dissection. It is used off label and on compassionate grounds, where other approved forms of intervention are no longer a viable option. The cases were performed in centers in continental Europe, North Africa, and Asia. Individual patient consent, institutional review board approval, and governmental dispensation were received at each institute before device implantation.
Study population. Out of 876 SMFM implanted globally, we have knowledge of 542. To date, 312 patients are maintained in the global registry, of which 38 patients were identified as having CSAD (12.2%). The study population included 33 male patients (86.8%) and five female patients (13.2%), with a mean age of 60.3 6 13.2 years (range, 26.9-84.8 years). Patients presented with the following: 82% had intercostal and abdominal pain, 15% had disabling claudication, two patients had spinal transient ischemic attacks and paresis, and three patients had hoarseness of voice. All patients were American Society of Anesthesiologists IV E; 90% of branches were off the compromised true lumen.
Indications included 35 Stanford type B dissections, two Stanford type A and B dissections, and one mycotic Stanford type B dissection. The latter patient had negative blood cultures at the time of the procedure. Fifteen patients (39.5%) had aneurysmal aortas, which were greater than 6 cm in diameter. Fourteen patients (36.8%) were reported to have had a previous aortic repair, including previous TEVAR, endovascular aneurysm repair (EVAR), and aortic arch repair.
All patients had complicated TBAD, which was defined according to Interdisciplinary consensus documents.
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There was one case in which the innominate artery was dissected and a case in which both the left carotid and left subclavian arteries were dissected. There were three cases in which the superior mesenteric artery arose from the false lumen, two incidents in which the celiac artery arose from the false lumen, and five cases in which the renal artery was supplied by the false lumen. All the remaining visceral branches arose from the true lumen.
SMFM device. A detailed description of the mechanism of action of Multilayer Flow Modulator (MFM) and its effects on peak wall stress, wall strength, intraluminal thrombus, endothelialisation, and side branch patency is beyond the scope of the present article, but is described in detail in an editorial by Sultan et al. 14 SMFM dissection technique. The dissection technique was employed by the article's corresponding author and is described so as to assist physicians in the optimal deployment of the SMFM.
All cases are assessed using EndoSize virtual deployment software (Therenva SAS, Rennes, France) with 20% oversizing (Fig 1) . The EndoSize software estimates how the SMFM will behave after deployment in terms of expected proximal and distal landing sites. This is crucial to gauge the number of devices required and the device lengths needed for full aortic coverage with minimum overlap of 6 cm in straight aorta and 8 cm in angulated areas.
If a side branch arises from the false lumen, endovascular scissoring using two 12 Â 6 mm balloons, one in the true and one in the false lumen, inflated simultaneously at the confluence of aortic bifurcation and pulled caudally using traction is undertaken to release the tough fibrotic wall from its attachment. An alternative method for septal scissoring is utilising a 12F sheath with two superstiff wires, one in the true lumen and one in the false lumen. The sheath is then gently pushed cranially, slicing the septum to equalize the true lumen with the false lumen.
ARTICLE HIGHLIGHTS
After ensuring that all side branches arise from the true lumen, the true lumen is accessed using a 4F pigtail catheter. The pigtail catheter is dynamically advanced using a 360 torque movement, during which 2-3 mL of 50% diluted dye are injected to guarantee that the catheter had been passed through the true lumen the whole way up to the coronary sinus. Any abnormal resistance during the dynamic advancement must be treated as re-entering into the false lumen.
The SMFM is inserted through a 20F introducer sheath for the large SMFM sizes. Because of the degree of foreshortening, the SMFM must be deployed at 1 cm per minute. The only exception to this is when the first SMFM is being deployed in the ascending aorta or arch. In this case, the first 10 cm of the SMFM can be deployed over 20 seconds as the heart has been stopped. During arch deployment, the interventionalist must push the rod of the delivery system to the outer curvature of the arch while unsheathing to accordion the device and "Endoquilt" the SMFM to abolish foreshortening.
Inflating a silicon balloon at the proximal or distal portion of the SMFM will rupture the balloon and so the wire mesh Unballoon (LeMaitre, Burlington, Mass) is preferable for bail out scenarios.
Virtual angioscopy. Using the virtual angioscopy tool in the EndoSize software confirms that the concept of a single proximal entry intimal tear and discrete distal reentry point did not exist in any of the 38 cases. Instead, the dissection occurs along the whole length of the aorta with numerous tears and perforations between the true and false lumens, irrespective of the dissection chronicity and maturity of the septum. This raises concern that if the whole aorta is not stabilized that uncovered aorta may be exposed to high shear stress and failure to induce false lumen thrombosis.
Study end points. Clinical endpoints were assessed and reported according to the DEFINE group end points. 12 The primary end point at 12 months was a composite of rupture and aneurysm-related death. The secondary end points were freedom of visceral branch occlusion, adverse events (ie, stroke, paraplegia and renal failure, and reintervention). Other outcome measures evaluated were technical success and the changes in total, thrombus, and flow volumes.
Statistical analysis. Survival was analyzed using KaplanMeier curves and reported up to the time point just before the standard error exceeded 10%. Diameters and volumes were presented as the mean 6 standard deviation. Interval changes were compared using a Studentpaired t-test. Statistical significance was defined at P value of #.05.
Morphologic analysis. The aortic dissections were assessed by two independent blind operators with each patient being assessed by both operators at baseline prior to SMFM placement, and then at 30 days, 3-, 6-, and 12-month intervals. The data for this study has been taken from the MFM Global registry, which uses a continuous sampling plan for quality assurance. 15 Computerized tomography angiogram images were examined using 3-mensio software (3-mensio Medical Imaging BV, Bilthoven, The Netherlands), and measurements were taken on maximum transverse aortic diameter, maximum longitudinal length, total, thrombus, and residual flow volumes.
False lumen volume index was calculated by dividing the false lumen volume, by the volume of the total aorta [ie, false lumen index ¼ false lumen volume/(total lumen volume þ false lumen volume)]. 16 A Student-paired t-test was used to examine statistical significance between pre-and postoperative morphologic findings, where P # .05 was considered to be statistically significant. 
RESULTS
Procedural success. Technical success was 97.4%, with one technical error, where the SMFM was deployed in the false lumen. Thirty-two cases (84.2%) were completed through a single groin approach. A mean of 1.96 6 0.95 devices were inserted per patient with a mean of 3.87 6 2.16 branches covered per patient. One hundred sixty-five branches were covered which included nine innominate arteries, 15 left common carotid arteries, 32 left subclavian arteries, and 109 visceral arteries.
The proximal landing zones ranged from zone 0 to zone 4 with the distal landing zone varying from zone 4 to zone 10. On average the treatment zone spanned 6.48 6 2.49 zones per patient (Table I) .
One-year survival. All-cause survival was 85.3% [95% confidence interval (CI), 67.1%-100%] after 12 months (Fig 2) . There were three patient deaths. One patient died of ventricular fibrillation 1-day postoperatively; this was not device-related but a procedure-related death. One patient died at 4 month from gastrointestinal hemorrhage, which was not device or procedure related. Another patient died at month 4, however, the cause of death was not reported to the registry.
Freedom from reintervention. Reintervention survival was 84.5% (95% CI, 65%-100%; Fig 3) , with three cases of reintervention within the 12-month period. Two patients had reinterventions within the initial 30 days and 5 months postoperatively for reasons that were not reported to the registry. One patient had a reintervention 2 months postoperatively, because of SMFM collapse. The stent was subsequently re-expanded via un-balloon angioplasty.
Neurologic sequalae. There was no incidence of stroke, spinal cord ischemia/paresis-paralysis or vertebral insufficiency reported.
Ischemic complications. Two cases of branch stenosis (<50%) and three cases of total occlusion were recorded preoperatively. One case of branch stenosis of the superior mesenteric artery (<50%) was recorded at 12 months. No vessels occlusions were recorded postoperatively. There were no incidences of visceral or renal insult, no incidences of target organ ischemia, or deterioration in postoperative renal function. There were no incidences of upper or lower limb ischemia.
Morphologic outcomes. Table II shows the overall morphologic analysis that was conducted. Mean transverse aortic diameter increased by 0.5 cm at 12 months (P ¼ .504). Mean aortic dissection length decreased by 2.3 cm (P ¼ .598). Mean total dissection volume decreased by 22.1 cm 3 (Fig 4, a; (Fig 7) , which was statistically significant at P # .05 (P ¼ .016).
Major adverse clinical events. Six major adverse clinical events occurred within the first 12 months of treatment. Freedom from major adverse clinical events at 3 months was 87.4% (95% CI, 72.1%-100%)
DISCUSSION
The International Registry of Acute Aortic Dissection had recommended TEVAR as first-line therapy for anatomically suitable patients with complicated TBAD. Conversely, mortality of open surgery for complicated acute type B dissection is up to 30%. [17] [18] [19] The Cleveland Clinic reported on TBAD, with open repair operative mortality of 8%, with 2.4% neurologic complications. Survival at 1, 2, and 3 years was 82%, 78%, and 75%, respectively, and 14% required reintervention. 20 Operative mortality in their TEVAR patients was 5%, and survival at 1, 2, and 3 years was 86%, 82%, and 80%, respectively, but reintervention was required in 22%. 19 In both open repair and TEVAR studies, freedom from adverse events was similar (55% at 5 years in the TEVAR and 50% in the open series). Subdiaphragmatic aortic pathology was predictive of the risk of death or reintervention in both groups. The STABLE trial investigators 4 reported an increase in false lumen thrombosis of 43.5% at 2 years, with growth of the abdominal aorta mainly attributed to failure of complete thrombosis and false lumen expansion. The obliteration of the false lumen is a key step in aortic remodeling. In the INSTEAD trial, there was a decrease in the false lumen diameter from 29.3 to 10.4 mm, which was associated with complete false lumen thrombosis in 90.6% of patients at 5 years. 6 Conrad et al 21 demonstrated that obliteration of the false lumen leads to decrease in false lumen diameter during long-term follow-up. They showed that in the nonstented aorta patients with a patent false lumen demonstrated an average growth of the unstented All-Cause Survival ReintervenƟon Free Survival aorta of >30% vs 3% in patients whose false lumen has thrombosed. Results similar to these have led investigators to suggest that further false lumen thrombosis may be promoted by extending stent coverage across the entire descending thoracic aorta. Hofferbeth et al 22 compared this technique with a cohort of patients treated with coverage of the proximal entry tear alone and found that patients with more descending thoracic aorta coverage were more likely to have complete false lumen thrombosis in the thoracic aorta (72% vs 46%) and abdominal aorta (40% vs 15%).
In the current series from the Global Registry, we observed false thrombosis with increasing number of stents used and a decrease in false lumen index within short-term 1-year follow-up. The SMFM enabled total aortic stenting with no limit to the extent of aortic coverage. Even in cases in which the false lumen was aneurysmal and branches arose from the false lumen, both factors known to be associated with adverse outcomes. 23 False lumen thrombosis occurred without compromising visceral or spinal cord perfusion. In the CSAD, there appears to be less consistent TEVARled aortic remodeling than in acute dissections, with total false lumen thrombosis ranging between 38% and 93%, and 17% of patients experiencing an increase in false lumen size in at least one location. 24 The complete false lumen thrombosis rate was 33%, and overall mortality was 18.2%. In the current SMFM series, only three reinterventions were required and no retrograde type A aortic dissections occurred. Additional concerns regarding TEVAR management of chronic TBAD aneurysms are the potential for endograft collapse because of a noncompliant dissection flap, visceral vessel ischemia, and intima-medial erosion. 36 Perhaps the most dreaded complication from these interventions is precipitation of retrograde dissection, which has been reported to occur in up to 4% of cases. 36, 37 These events underscore the current limitations of stent graft design for chronic dissection because, in the majority of cases, treatment extends to aortic arch, and the endograft has to adapt to significant differences in lumen diameter between the proximal and compressed distal true lumen. From the literature it is evident that time specific treatment and treatment modalities still vastly disagree in relation to aortic dissection. The SMFM may offer a novel resolution to this question. Unlike a traditional covered stent graft, the SMFM has the ability to cover vessels while maintaining adequate perfusion to the branches, because of the nature of its mesh design. This in turn leads to less traumatic operative intervention and less recovery time for patients. In fact, computational results show that the SMFM improves the flow velocities into the false lumen branches in these cases. 38 Therefore, the SMFM may altogether negate the use of a hybrid treatment, especially in the case of ascending aortic dissection, arch and across the visceral and spinal branches without fear of end-organ malperfusion or paraplegia. Results in our cases show that there were no incidents of malperfusion, endorgan ischemia, stroke or paraplegia across the treatment cohort. The SMFM is not currently approved for treatment of aortic dissection, therefore, there are few recorded or published studies to compare with. Chocron et al 9 published a case report in which treatment consisted of replacement of the ascending aorta extending to the aortic arch, with re-implantation of the innominate artery and two SMFM's placed from the left subclavian to below the renal arteries. Three-month computed tomography scan showed that the thoracic false lumen was no longer patent. According to the initial 12-month results in the current study, transverse aortic diameter was relatively unaffected by the presence of the SMFM, with an overall increase in diameter. This increase in aortic diameter may be linked to an increase in aortic thrombus volume. These trends in diameter and volume may owe to the fact that 14 patients out of the total cohort had aortic diameters greater than 6 cm preoperatively. The length of the dissected aorta was shown to decrease in 12 months. The SMFM instructions for use recommend covering the entire length of the diseased aorta with the device, from normal aorta proximally, to normal aorta distally. The reduction in dissection length indicated that there was no further progression of the disease, both proximally and distally. Increased true lumen volume and reduced false lumen volumes are positive results. Dissection remodeling was indicated by the reduction in longitudinal length, and false lumen volume of the dissected aorta. A statistically significant reduction in false lumen index (P ¼ .016) at 12 months, and increase in true lumen volume (P ¼ .053) between 6 and 12 months, furthermore, confirmed dissection remodeling.
All-cause survival was 85.3% at 12 months, with three patient deaths recorded. There were no reported aortic ruptures. Initial retrospective evaluation of the registry data en masse has illustrated a number of operatorrelated errors that have been commonly recorded. These include device foreshortening resulting in inadequate overlap of devices or device dislocation, poor SMFM sizing often undersizing, and inadequate overlap between devices or device foreshortening, which can result in failure mode I or between two overlapping stents, resulting in failure mode II. 39 The authors postulate that treatment of CSAD with the SMFM equalize arterial pressure between the true and false lumen. This thereby stabilizes the injured aortic wall, and reduces aneurysm formation as it covers normal-to-normal aorta without compromising the side branches. A recent publication from Lowe et al, 41 on the United Kingdom pilot study of the MFM has reignited controversy about the device. 41 It is not directly comparable to the current study, as it reports on thoracoabdominal and pararenal aneurysms, but it is worth discussion. The UK study reports outcomes from a single center using the first generation device on just 14 high-risk patients. All the patients were assessed and deemed unsuitable for either open repair or fenestrated EVAR/ branched EVAR, the latter being confirmed by the fenestrated EVAR/branched EVAR endograft manufacturers. The authors report that the MFM devices failed to influence the natural history of thoracoabdominal aortic aneurysms with 1-year survival of 79% and aneurysm sac stabilization in just two patients. However, lack of universal experience with the device meant that the stents were placed in patients whose aneurysm were too large with eight of the 14 patients (57%) having an aneurysm diameter greater than 6.5 cm. The devices were undersized with inadequate overlap and were deployed too quickly, thereby iatrogenically enhancing the degree of foreshortening.
A more in depth analysis of the data, on these 14 patients, which was voluntarily submitted to the Global Registry, was undertaken on an extended follow-up from February 2011 to November 2015, with the longest patient follow-up being 32 months. Death occurred in two patients (14.3%) because of aneurysm rupture and in these cases, technical faults were evident with inadequate device overlap and failure to place the device in landing zone which had healthy aortic wall. One of these patients also had a coagulation disorder and presented with contained rupture of the aorta, both of which are contraindications and render the device used outside of instructions for use. Seven patient deaths (50%) occurred because of nonaneurysm-related events: pneumonia, myocardial infarction (two patients), multiorgan failure, liver disease, and two unknown causes. Review of these patients showed technical faults in five cases (35.7%). These faults included implanting the device against indications for use in four cases (28.6%) (Shaggy aorta with irregular thrombus deposition and embolization in three cases and highly calcified noncompliant aorta at the landing zones in two cases). Of particular note, in four cases (28.6%), a single iliac limb was not placed within the main aortic stent, rather within the aneurysm sac, which subsequently led to occlusion of the iliac stent (Fig 8) . These types of technical errors led to device-related events, such as dislocation, occlusion, and collapse of the stents. Morphologic analysis demonstrated that most aneurysms expanded during the observed procedure period. Five patients (35.7%) were surviving at the end of the observed procedure period, however, review of their computed tomographies show technical faults are evident with an increase in aneurysm size in three patients.
Out of 14 high-risk patients with no other treatment options, aneurysm-related deaths occurred because of multiple factors including a high rate of technical error. As with any new device to market, proctoring is certainly required, and this device like any other aortic device should not be implanted by physicians who have not been trained on device sizing and deployment techniques. Strict instructions for use must be followed to ensure best patient selection and outcome. All aortic endograft devices are released to the market with Indication for Use, which have been agreed with the appropriate regulatory bodies. These indications limit the use of the device according to various anatomic and/or comorbid restrictions. In this regard, the SMFM is no different to any other aortic device on the market, and it too cannot be used in certain patients in whom particular anatomic or comorbid conditions exist. It must be noted that in the United Kingdom study that devicerelated events occurred not only as a result of technical error, but also because of a lack of proactive reintervention in numerous cases.
The data is limited by the accuracy of information contributed by the treating physician with lack of longitudinal follow-up in 75% of patients. The registry is totally voluntary, and no incentives, including financial, are provided to those who submit data. We are relying solely on the integrity and goodwill of implanting physicians and their desire to contribute to clinical science. The Global Registry is, therefore, plagued with the limitations in terms of data comprehensiveness, accuracy and completeness.
